Catalent Pharma Solutions, a leading solution provider for inhaled drug product development, has planned a major investment of $20 million to expand its industry leading inhalation drug development, delivery and supply capabilities by enhancing their Inhalation Centre of Excellence in Research Triangle Park (RTP), North Carolina. This planned investment will focus on expanding pressurized Metered Dose Inhaler (pMDI) clinical and commercial supply capabilities as well as other enhancements to the facility.

“Pulmonary and nasal represents the second largest drug delivery market by delivery route. Catalent’s investment in commercial manufacturing at our Inhalation Centre of Excellence not only fits with our advanced drug delivery growth strategy, but also positions us as a world leader supporting inhaled products,” commented Scott Houlton, president of Catalent’s Development and Clinical Services business. “In addition to the introduction of scalable processes for micro-dosing inhalation powder formulations, and the recent commissioning of our new nasal filling suite, this $20 million investment will upgrade our pMDI manufacturing capacity and allow us to better support our customers from early development all the way through to commercialisation; bringing more products and better treatments to market faster.”

Catalent, one of world’s leading solution providers for inhaled drug product development, provides a broad range of inhalation services including API optimization, pre-formulation, formulation, analytical testing and manufacturing across all inhaled dosage forms at the RTP, NC facility, and its advanced aseptic development and fill/finish supply solutions facility in Woodstock, Illinois.